← Human Trials & Peer-Reviewed Studies
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Plain-language guide to NCT06482112: phase 2 randomized trial of Efinopegdutide, fatty liver & elevated liver enzymes, 124 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06482112
- Phase
- phase 2
- Status
- completed
- Start
- 2024-07-29
- Completion (planned or actual)
- 2025-06-27
- Participants
- 124 (actual)
- Design
- randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-alcoholic Fatty Liver Disease; Nonalcoholic Fatty Liver Disease; Liver Disease
- Results posted
- yes
What This Study Did, in Plain Language
What Was Tested
This registered phase 2 trial tested Efinopegdutide for fatty liver & elevated liver enzymes.
It had three arms (groups): one (active comparator), one (experimental) and one (experimental).
The registry classes the interventions as drug.
Who Took Part
124 actual participants took part.
It was open to people of any sex aged from 18 years up to 80 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
The full record lists 2 inclusion and 9 exclusion criteria; among the exclusions: has a history or evidence of chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (masld) or metabolic dysfunction-associated steatohepatitis (mash); has a history of pancreatitis; has a history of type 1 diabetes mellitus (t1dm), diabetic ketoacidosis, or diabetes secondary to pancreatectomy.
How the Study Was Run
It was run as a randomized, parallel-group and open-label study.
Random assignment meant chance, not the researchers, decided who got Efinopegdutide and who got the comparison, which limits bias.
Groups ran in parallel: each of the fatty liver & elevated liver enzymes participants stayed in one arm throughout.
Being open-label, the Efinopegdutide study did not mask who received what.
It started in 2024-07-29 with completion listed for 2025-06-27.
It ran at 39 sites in United States (36) and Puerto Rico (3).
Its stated primary purpose is treatment.
What Was Measured
Primary outcome: Percentage of Participants Who Experienced an Adverse Event (AE) (time frame: Up to Week 32). Percentage of Participants Who Discontinued Study Intervention Due to an AE (time frame: Up to Week 28).
It also tracked 1 secondary outcome, for example Mean Percent Change From Baseline in Body Weight at Week 28.
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Efinopegdutide in 124 people with fatty liver & elevated liver enzymes.
The trial is marked completed; results are posted on the registry, and this page does not restate them.
More context: the Efinopegdutide compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compound
Efinopegdutide: A long-acting GLP-1/glucagon dual agonist from Merck studied for MASH.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.